What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

Gynecol Oncol. 2007 Apr;105(1):3-6. doi: 10.1016/j.ygyno.2007.01.038.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Angiogenesis Inhibitors / adverse effects*
  • Angiogenesis Inhibitors / therapeutic use
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Clinical Trials, Phase II as Topic
  • Female
  • Humans
  • Intestinal Perforation / chemically induced*
  • Intestinal Perforation / therapy
  • Neovascularization, Pathologic / drug therapy
  • Ovarian Neoplasms / blood supply
  • Ovarian Neoplasms / drug therapy

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab